Prostatype Genomics AB (publ)

DB:PGO0 Stock Report

Market Cap: €922.9k

Prostatype Genomics Past Earnings Performance

Past criteria checks 0/6

Prostatype Genomics's earnings have been declining at an average annual rate of -33.9%, while the Biotechs industry saw earnings growing at 7.7% annually. Revenues have been declining at an average rate of 0.3% per year.

Key information

-33.9%

Earnings growth rate

26.8%

EPS growth rate

Biotechs Industry Growth-14.6%
Revenue growth rate-0.3%
Return on equity-305.1%
Net Margin-985.2%
Next Earnings Update13 Feb 2025

Recent past performance updates

Recent updates

Revenue & Expenses Breakdown

How Prostatype Genomics makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

DB:PGO0 Revenue, expenses and earnings (SEK Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Jun 244-41182
31 Mar 244-43193
31 Dec 234-41183
30 Sep 233-40173
30 Jun 231-37144
31 Mar 231-31123
31 Dec 221-29104
30 Sep 221-27103
30 Jun 221-2392
31 Mar 222-1882
31 Dec 213-1681
30 Sep 213-1471
30 Jun 213-1470
31 Mar 213-1571
31 Dec 203-1462
30 Jun 203-952
30 Jun 193-951
30 Jun 185-953
30 Jun 175-522
30 Jun 160-1132

Quality Earnings: PGO0 is currently unprofitable.

Growing Profit Margin: PGO0 is currently unprofitable.


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: PGO0 is unprofitable, and losses have increased over the past 5 years at a rate of 33.9% per year.

Accelerating Growth: Unable to compare PGO0's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: PGO0 is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-20.8%).


Return on Equity

High ROE: PGO0 has a negative Return on Equity (-305.15%), as it is currently unprofitable.


Return on Assets


Return on Capital Employed


Discover strong past performing companies